Abstract: Provided herein are compositions, systems, kits, and methods for treating IL-17a related diseases and conditions using an SBE nucleic acid sequence that binds a SEFIR domain of an ACT1 protein.

Abstract: Provided herein non-human transgenic animals comprising a genome that: i) under-expresses, or is inducible to under-express, Hu Antigen R (HuR) in at least some neurons of said transgenic animal; ii) does not express HuR, or is inducible to not express HuR, in at least some neurons of said transgenic animal; or iii) does not express functional HuR, or is inducible to not express functional HuR in at least some neurons of said transgenic animal, as well as methods of screening drugs and therapies (e.g., useful in treating ALS) using such animals.

Abstract: The present invention discloses a highly efficient and intelligent drug and parenteral nutrition product automatic collation and reversion device, which comprises a feeding conveyor belt, a discharging conveyor belt, a returning conveyer belt and computer; and in the junction of the feeding conveyor belt, the discharging conveyor belt and the returning conveyer belt is provided an inspection module. In the present invention, drug dispatch is configured to be done just as a production line, by providing a weighing scale to measure the weight of drugs, and four cameras to assist in identifying drugs to check whether correct drugs are dispatched, and in case that any errors detected, the wrong drugs will be sent back to the original position for inspection, which improves efficiency and accuracy of drug dispatch and reduces manpower cost.

Abstract: The present invention describes compounds according to formula I: and compounds according to formula II: and additional related flavonoid compounds, as well as the use of the compounds in methods for the prevention or treatment of IL-17A-mediated disease in a subject.

Abstract: Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.

Abstract: A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the ?C helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.

Abstract: A drive plate of an electromagnetic-fan clutch comprises: a body of the drive plate provided with magnetic-insulation air holes, connection ribs, and magnetic conductive layers. The magnetic-insulation air holes and the magnetic conductive layers are arranged alternatively along a radial direction of the body of the drive plate. A friction-increasing groove is opened on the magnetic conductive layer. The thickness of the magnetic insulation air holes and the thickness of the connection ribs are less than the thickness of the magnetic conductive layers. Six connection ribs are distributed uniformly between the magnetic conductive layers, and the connection ribs at two sides of the magnetic conductive layer are distributed along the radial direction of the body of the drive plate at an interval of 30 degrees. A drive plate through hole is opened in the body of the drive plate, and accommodation walls are disposed on the magnetic conductive layers.

Abstract: A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the ?C helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.

Abstract: Disclosed are externally connected time port changeover method and device. The method includes: a node serving as a GM node transmitting time information via a first externally connected time port of the node; if the first externally connected time port fails, the node updating current node priority and GM node priority of the node as preset node priority which is node priority configured for the node when the node is activated; and the node judging whether a second externally connected time port of the node is up and the priority of the second externally connected time port is higher than the current GM node priority, if so, activating the second externally connected time port to transmit the time information. The problem that when the currently selected time access port has failed, changeover among ports cannot be completed in time is solved, thus improving the stability of the time synchronization network.

Abstract: The present invention describes compounds according to formula I: and compounds according to formula II: and additional related flavonoid compounds, as well as the use of the compounds in methods for the prevention or treatment of IL-17A-mediated disease in a subject.

Abstract: The present invention relates to a biomass gas and biomass charcoal preparation system, including three successive working units: a feeding unit, a pyrolysis reaction unit, and a discharging unit, and further having a pyrolysis reaction control system. The pyrolysis reaction unit has a pyrolysis reaction body. The pyrolysis reaction body is provided therein with a helical propulsion device and an air supply device. The pyrolysis reaction body is a rectangular cavity having a metal shell. The cavity of the pyrolysis reaction body is divided into two parts: an upper part and a lower part that are separable.

Abstract: A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the ?C helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.

Abstract: An ultra-short-term forecasting method including real-time monitoring of the effect of upper and lower courses, comprising: obtaining ultra-short-term model forecast results through the model lattices based on the T639 global spectral model course library data source, the CALMET wind field diagnostic model and static data; establishing statistical equations on the effect of upper and lower courses between the corresponding reference index station and each target wind tower for obtaining the effect of upper and lower courses of the target wind towers based on the wind tower database of the target wind power base and combined with the wind direction and speed real-time monitoring data of the reference index stations in the upper and lower courses, forecasting the ultra-short-term wind speed changes of each target wind tower and correct combined with the ultra-short-term model forecast results to form forecasting of the ultra-short-term wind speed changes of the wind towers in the target wind power base; after r

Abstract: A method of producing an IgG type monoclonal antibody in vitro is described. The method includes the steps of: (A) providing B-cells obtained from a transgenic non-human mammal whose genome comprises a disruption of an Act1 gene; (B) contacting the B cells with an antigen under conditions which result in formation of an antibody specific to the antigen by the B cells; (C) fusing the B cells with one or more immortal cells, to produce one or more hybridomas which express IgG type monoclonal antibodies that specifically bind to the antigen; (D) selecting a hybridoma which expresses an antibody specific to the antigen; and (E) obtaining monoclonal antibody produced by the selected hybridoma. Kits for carrying out the method of producing an IgG type monoclonal antibody are also described.

Abstract: Disclosed are externally connected time port changeover method and device. The method includes: a node serving as a GM node transmitting time information via a first externally connected time port of the node; if the first externally connected time port fails, the node updating current node priority and GM node priority of the node as preset node priority which is node priority configured for the node when the node is activated; and the node judging whether a second externally connected time port of the node is up and the priority of the second externally connected time port is higher than the current GM node priority, if so, activating the second externally connected time port to transmit the time information. The problem that when the currently selected time access port has failed, changeover among ports cannot be completed in time is solved, thus improving the stability of the time synchronization network.

Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Abstract: The present invention provides a transgenic non-human mammal which lacks a functional Act1 gene referred to herein as a “transgenic non-human Act1 knockout mammal” or a “Act1 knockout mammal”. In a particular embodiment, the genome of the Act1 knockout mammal comprises at least one non-functional allele for the endogenous Act1 gene. Thus, the invention provides a source of cells (for example, tissue, cells, cellular extracts, organelles) and transgenic non-human mammals useful for studying Act1. Further aspects of the invention provide methods for producing transgenic non-human Act1 knockout mammals and transgenic non-human Act1 deficient mammals produced by the methods; targeting vectors for use in producing Act1 deficient mammals; methods for the identification of agents (for example, diagnostic or therapeutic agents) which inhibit or mimic Act1 activity; and methods of identifying agents that can be used to treat and/or prevent a disease or condition associated with a defect in Act1 (e.g.

Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.